Bruce Variano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bruce Variano has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ruth B. Merkatz
Center for Biomedical Research, Population Council, New York, NY, USA
2 shared publications Clement M. Haeck
Center for Biomedical Research, Population Council, New York, NY, USA
1 shared publicationElena Hoskin
Population Council, Inc., Center for Biomedical Research, 1230 York Avenue, New York, NY 10065; UCSF Dept of Ob/Gyn, Reproductive Endocrinology & Infertility, Mission Hall, 550 16th Street, 7th floor, Campus Box: 0132, San Francisco, CA 94158
1 shared publication- Elena Martinelli
Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
1 shared publication Fermin F.H. Aragon
Center for Biomedical Research, Population Council, New York, NY, USA
1 shared publication- George W. Creasy
Columbia Laboratories, Inc., Livingston, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 19 May 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (5) , 751
The Vaginal Microbiota, Bacterial Biofilms and Polymeric Drug-Releasing Vaginal Rings
The diversity and dynamics of the microbial species populating the human vagina are increasingly understood to play a pivotal role in vaginal health. However, our knowledge about the potential interactions between the vaginal microbiota and vaginally administered drug delivery systems is still rather limited. Several drug-releasing vaginal ring products are currently marketed for hormonal contraception and estrogen replacement therapy, and many others are in preclinical and clinical development for these and other clinical indications. As with all implantable polymeric devices, drug-releasing vaginal rings are subject to surface bacterial adherence and biofilm formation, mostly associated with endogenous microorganisms present in the vagina. Despite more than 50 years since the vaginal ring concept was first described, there has been only limited study and reporting around bacterial adherence and biofilm formation on rings. With increasing interest in the vaginal microbiome and vaginal ring technology, this timely review article provides an overview of: (i) the vaginal microbiota, (ii) biofilm formation in the human vagina and its potential role in vaginal dysbiosis, (iii) mechanistic aspects of biofilm formation on polymeric surfaces, (iv) polymeric materials used in the manufacture of vaginal rings, (v) surface morphology characteristics of rings, (vi) biomass accumulation and biofilm formation on vaginal rings, and (vii) regulatory considerations.
- 19 May 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (5) , 751
Open AccessThe Vaginal Microbiota, Bacterial Biofilms and Polymeric Drug-Releasing Vaginal Rings
The diversity and dynamics of the microbial species populating the human vagina are increasingly understood to play a pivotal role in vaginal health. However, our knowledge about the potential interactions between the vaginal microbiota and vaginally administered drug delivery systems is still rather limited. Several drug-releasing vaginal ring products are currently marketed for hormonal contraception and estrogen replacement therapy, and many others are in preclinical and clinical development for these and other clinical indications. As with all implantable polymeric devices, drug-releasing vaginal rings are subject to surface bacterial adherence and biofilm formation, mostly associated with endogenous microorganisms present in the vagina. Despite more than 50 years since the vaginal ring concept was first described, there has been only limited study and reporting around bacterial adherence and biofilm formation on rings. With increasing interest in the vaginal microbiome and vaginal ring technology, this timely review article provides an overview of: (i) the vaginal microbiota, (ii) biofilm formation in the human vagina and its potential role in vaginal dysbiosis, (iii) mechanistic aspects of biofilm formation on polymeric surfaces, (iv) polymeric materials used in the manufacture of vaginal rings, (v) surface morphology characteristics of rings, (vi) biomass accumulation and biofilm formation on vaginal rings, and (vii) regulatory considerations.
- 1 March 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 596, 120234
Polymorphism characterization of segesterone acetate: A comprehensive study using XRPD, FT-IR and Raman spectroscopy
- 1 March 2021
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 596, 120234
Polymorphism characterization of segesterone acetate: A comprehensive study using XRPD, FT-IR and Raman spectroscopy
- 1 March 2018
- Published by Elsevier in Contraception
- Vol. 97 (3) , 270-276
Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug–drug interaction study
- 1 March 2018
- Published by Elsevier in Contraception
- Vol. 97 (3) , 270-276
Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug–drug interaction study